Tag: biopharmaceutical products

Pharma packaging industry

Opportunities and Challenges in the Global Biopharmaceutical Market

Biopharmaceuticals is currently at the core of the pharmaceutical sector. The opportunities in the global biopharmaceutical market are big and growing too rapidly. In fact, biopharmaceuticals generate global revenues over $150 billion, making up about 20 per cent of the total pharma market. It’s by far the fastest-growing part of the industry. Biopharma’s current annual growth rate is double that of conventional pharma, and the growth is expected to continue at that rate for the foreseeable future. However, the global pharmaceutical market is not entirely free of challenges and flaws. As biopharma companies move from the scientific frontier to the business mainstream, the companies in the global biopharmaceutical market will increasingly be forced to confront the same challenges of maintaining competitiveness by ensuring affordability, quality, and delivery performance.

Only through deep operational excellence can biopharma companies fulfill its potential to transform the health expectations of millions of people across the globe and successfully navigate both the promising and challenging elements of the sector. Request a free proposal to know how we help our clients in the biopharma sector achieve this.

Opportunities in the biopharmaceutical industry

Biopharmaceutical products are known for their efficacy and safety. Furthermore, the ability of these products to address and cure previously untreatable conditions allows companies in the global pharmaceutical market to command high prices for new and innovative drugs. Despite the high prices, the strong demand for biopharma products are driving sales and profitability in this market. According to our pharma industry analysis, investments made in the global biopharmaceutical market has yielded better returns than the pharma industry average, prompting clinical trials to become unprecedently high. The success of the clinical pipeline will lead to a higher number of new molecule launches, rising from a handful a few years. Moreover, robust, low-cost genetic profiling will improve treatment outcomes and serve to accelerate and enhance the outcomes of clinical trials, helping to reduce the cost of drug development.

Challenges in the global biopharmaceutical market

Managing demand for improved access

The downward cost pressure is expected to intensify with healthcare systems increasingly attempting to balance the rising demand with the reducing budgets. Consequently, payers may also find it challenging to justify the annual treatment costs demanded for some biopharmaceutical products. Furthermore, governments in emerging markets understand the critical role that biopharma will play in boosting healthcare outcomes, and they are demanding alternative ways to fulfill the rising demand for these products.

Many of the next major opportunities for biotech will require companies to develop new and different technologies and operating models. Get in touch with our experts to know how we can help you stay updated with latest innovations and strategies for success in the global biopharmaceutical market.

Quality compliance and regulatory scrutiny

Companies in the global biopharmaceutical market are struggling to keep up with the rising demands of regulators, primarily the US Food and Drug Administration. In the last five years, the industry has been subject to an unprecedented number of warning letters, and scrutiny is unlikely to decrease. Furthermore, the rising relevance of global markets (beyond the United States, European Union, and Japan) is increasing the complexity of multiple quality standards and regulatory regimes. Compliance, robustness of processes, and efficiency are keys to success for companies in the global biopharmaceutical markets.

Complexity in supply chain operations

The complexity of supply chain operations of companies in the global biopharmaceutical market are bound to increase with the rise of new processes and technologies. Moreover, the current production programs are already stretching the industry as even several top biopharmaceutical companies are failing to deliver to the market.

Know more about how Infiniti can help overcome key challenges faced by companies in the global biopharmaceutical market.

Trends in pharmaceutical industry

Pharmaceutical Industry Challenges to Watch Out for in 2019

Despite several major challenges in the way over the past couple of years, the pharmaceutical industry continues to thrive. However, the sector is not completely free from challenges this year either. Due to the nature of the industry, cost aspects and stricter regulations remain as constant pharmaceutical industry challenges. Furthermore, pharma companies are also under scrutiny by health insurers, consumers, and the government for greater transparency and accountability. In this blog, industry thought leaders from Infiniti Research gives an overview of the current scenario in the pharma industry and also discusses the key pharmaceutical industry challenges that companies can expect this year.

Pharmaceutical industry challenges 2019

Pharmaceutical industry challenges 2019Patent cliffs

The expiry of a drug patent and the consequent drop in the sales of the product which previously held a large market share is known as a patent cliff. These patent cliffs give competitors the opportunity to produce and patent a comparable brand name drug. In the next couple of years, this is going to be one of the key pharmaceutical industry challenges affecting prescription drug sales worldwide.

As the pharma industry becomes increasingly globalized, complex, and highly regulated, the sector must become more streamlined and cost-efficient at manufacturing and distributing its products. Request a free proposal to know how our solutions can help you streamline your operations and overcome critical pharmaceutical industry challenges.

Foreign counterfeit drugs

The increasing flow of foreign counterfeit drugs into the American market is another key challenge that would affect pharma companies in a big way. As several pharmaceutical manufacturers are moving abroad to attain lower costs, it must be ensured that they meet the U.S. quality standards while adhering to the local regulations overseas. It is also essential to block all illegal trafficking of counterfeit medications. In order to achieve this, stringent regulations and standards must be imposed on all vendors and third parties involved in the manufacturing and transportation of pharma products. For pharma companies operating out of or distributing drugs in the UK, Brexit will make it even more difficult.

US drug prices

The issue of rising drug costs in the US continues to persist. The price freezes in 2018 was a result of constant pressure from patients, politicians, and other regulatory bodies. As a result, a proposal was made to introduce an international pricing index through Medicare with the aim of reducing Medicare spending considerably. This proposal was widely criticized due to concerns and to add on to the pharmaceutical industry challenges several companies hiked their prices even further in the early 2019. One of the key pharmaceutical industry challenges in the US right now is to control drug prices and provide more accessible and affordable healthcare to the Americans.

Have unanswered questions about the current pharmaceutical industry challenges and how our solutions can help you formulate effective strategies to overcome them? Get in touch with our experts for queries relating to our services for pharma companies.

Shift to patient-centric healthcare

The advent of technology has made the patients more informed and they are now likely to play a more active role in any treatment plan prescribed by their doctor. While patient-centric healthcare provides several opportunities, it can also add on to the current pharmaceutical industry challenges. The primary challenge will be to determine how to leverage the power of health technology and focus on partnerships directly with the customers rather than with the medical community. In order to survive despite the rising prices, companies in the pharma industry must foster better relationships and build trust with the consumers. Also, the rising consumerism has prompted customers to look at prescriptions from a more value-benefit perspective. As healthcare consumerism rises, pharma companies must find ways to provide real-world research backup claims to justify their products and prices.

Learn more about our market intelligence solutions

biopharma industry

Top Trends Shaping the Asian Biopharma Industry

Some of the earlier events in Asia, such as China’s market access blockade, Japan’s spending controls, and deceleration in Southeast Asia and India have contributed towards a flat enthusiasm for the biopharmaceutical sector in Asia. However, certain recent trends have reignited the interest in biopharma in this region, with key implications for pharma executives.

Asia is popular for its dynamic markets and its rapid growth. Although over the past year the enthusiasm in the region for biopharma has been flat, several recent biopharma trends have turned the tables. This has brought about several market changes that make it essential for companies to reassess their strategy and go-to-market model. In this blog, biopharmaceutical industry experts at Infiniti Research discuss some of the recent biopharmaceutical industry trends in Asia and share perspectives on their implications for executives in biopharmaceutical companies.

Would you like to learn more about our solutions for the healthcare industry? Request a free brochure for insights into our services portfolio and learn how we help global clients overcome their business challenges!

Key biopharma trends in Asia

CDFA reforms in full stride in China

The recent China Food and Drug Administration (CFDA) reforms are more optimistic fundamentals that aim to support industry growth through innovation. Over the past few years, the CDFA has made significant strides in terms of addressing critical gaps in the system. Furthermore, there have been several reforms published on the drug-registration policy. These policies have been designed to improve the registration process and to encourage companies in the biopharmaceutical industry to bring innovation to China. This includes therapies for addressing severe and rare diseases and fast tracking approval for therapies. As a result of these new drug approvals, a record number of approvals and new product launches were seen over the last couple of years. The biopharma industry in China is accelerating against the backdrop of the new CDFA reform.

Price reforms in Japan

The Japanese ministry of health made a proposal in 2017 to overhaul the current drug pricing regulations. This reform will affect both the new drug pricing and in market pricing revisions across all drug categories including off-patent long-listed products, patented prescription drugs, and generics. This includes changes such as narrowing price maintenance premium (PMP) for patented products. The PMP will now be applicable only to selected drugs and full premium will be awarded only to a subset of companies. The scope of the premium will be limited to innovative drugs and the amount of premium will be matched to a company’s contribution to R&D.

Emerging fund pools in Southeast Asia and China

In China, there has been an upward trend in the expansion of reimbursement of innovative drugs. Furthermore, companies in the biopharma industry in China have also started to experiment with new models to improve patients’ access to medicines. China remains an important growth engine for companies. With these biopharma trends and changing outlook in China, the country remains a highly lucrative market and an important growth engine for companies in the biopharma industry.

Stay current on the latest market updates and leverage advanced solutions to achieve your business goals. Request a free proposal for more insights on how our solutions can help your business.

Digital and advanced analytics in healthcare

Although big data and other digital technologies have been constant buzzwords in the biopharma industry in Asia, now we are seeing their gradual uptake by several companies in the sector. Governments in Asian countries like China and Japan have introduced policies to promote the application of such advanced biopharma trends. Furthermore, even physicians and medical reps, especially in Japan, have already shifted away from pharmaceutical sales reps as their primary information source and use digital channel as their primary source. In China, for instance, studies show that doctors spend over two hours of their working day on an average online and have switched from computers to smartphones to support many of their professional activities. Consequently, digitalization is going to be one of the key biopharma trends that are going to revolutionize Asia.

Learn more about Infiniti’s solutions for business.

IR36

Impact of Target Market Segmentation on Consumer Demand: A Success Story on How We Assisted a Leading Biopharmaceutical Products Manufacturer

Biopharmaceutical products play a significant role in enhancing the lifestyle and reducing death rates in patients with cancer, HIV, rheumatoid arthritis, and cystic fibrosis.  The efficacy and safety of drugs drive the growth of the global biopharmaceutical products manufacturing sector. In the pharmaceutical industry, the biopharmaceutical segment deals with the manufacture of drugs using living biological systems. Therefore, the production of biopharmaceutical products requires specialized equipment and devices that can support these biological systems.

Also, the costs associated with the procurement of this equipment is high when compared with the ordinary manufacturing equipment. Several such factors act as a restraint, adding to the requirement of moreIR_RFP resources and time to set up a biopharmaceutical manufacturing facility.

The global biopharmaceutical industry subsegments include:

  • Generic drugs
  • Chemically derived drugs
  • Biosimilars
  • Biologics
  • Over-the-Counter (OTC) drugs

The Business Challenge

The client– A prominent manufacturer of biopharmaceutical products.

A pharmaceutical industry client, specializing in the manufacture of biopharmaceutical products, wanted to leverage market segmentation based strategies to gain detailed insights into the target market groups. The client was looking at identifying the most profitable way to segment end-user groups into different segments. The client also wanted a detailed report on the demographic, geographic, and psychographic variables of the end-users in various segments. Also, by using target market segmentation strategies, the client wanted to outline their business plans to reach end customers.

Additionally, the biopharmaceutical products manufacturer was looking at enhancing their marketing strategy to improve product reach. They also wanted to identify potential customers in every target market and focus on developing personalized strategies using market segmentation solutions.

Results– Offered detailed insights into the different market segments and helped the client analyze consumer demand based on a robust market segmentation strategy.

Market Segmentation

Want more information about our target market segmentation strategy solutions for the pharmaceutical industry?

Ask an analyst

The Journey

Infiniti’s target market segmentation experts carried out extensive research comprising interviews and discussions with leading stakeholders in the biopharmaceutical products manufacturing industry to help the client develop an integrated customer development process. The market segmentation experts also compiled information from a wide array of secondary sources such as paid industry databases, company presentations, and industry forums.

The Solution and the Business Impact

With the help of Infiniti’s target market segmentation strategy, the biopharmaceutical products manufacturer was able to divide and gain detailed insights into the various market segments. Leveraging market segmentation strategies also helped them to focus on developing a heterogeneous approach to meet the needs of several different sub-targets. 

The market segmentation strategy also offered detailed information on the psychographics and demographics of the target markets while taking into account the consumer demand for different segments.


The Future

The global market for biopharmaceutical products continues to evolve with the expectation of a positive future with several growth opportunities. The growing demand for bioprocessing technologies will prove to be a significant growth driver for this market segment in the coming years. In response, several leading pharmaceutical establishments are now increasing development efforts on biopharmaceuticals products. Moreover, technological innovations are driving several industry trends, leading to better innovations in drug development.

Biopharmaceutical industry trends:

  • Demand for single-use systems and disposable devices- Several leading pharma products manufacturers are now adopting disposable devices. Breakage and loss of production material may cause significant problems to their usage and adoption rate. However, since breakage is a relatively rare occurrence, such hurdles are becoming increasingly less of a problem.
  • Demand for continuous processing- There’s a growing demand for the continuous processing technologies from the end-user segments. Suppliers in the pharmaceutical industry have also increased their investments in R&D to develop such systems. This also resulted in many companies introducing chromatography and other multi-column systems for continuous purification.

Trends in the biopharmaceutical products manufacturing sector remain very positive, with no significant threats on the horizon and healthy industry growth occurring globally.  The industry will continue to grow at a steady pace, providing new growth opportunities for those who recognize the regulated nature of this industry.


A must-read case study for strategy specialists and decision makers looking to develop an understanding of the pharmaceutical industry.

IR_RFP